Glaxosmithkline Pharmaceuticals Ltd vs Pentokey Organy India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2362 as of 05 May 15:30 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Pentokey Organy (India) Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Pentokey Organy (India) Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Pentokey Organy (India) Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Pentokey Organy (India) Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Pentokey Organy (India) Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Pentokey Organy (India) Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Pentokey Organy (India) Ltd

Pentokey Organy (India) Ltd was incorporated on November 26, 1986.
The Company is engaged in the trading of Pharmaceutical products such as Acetic Acid, Ethyl Acetate and Acetaldehyde.
Ethyl Acetate is preferred by customers in all markets as it is fast replacing the petroleum-based solvents such as Toluene, MEK (Methyl Ethyl Ketone), MIBK (Methyl Iso Butyl Ketone) etc. In 2012-13, the production of intermediate product namely Acetic Acid was not competitive due to market prices.
Company therefore purchased the Acetic Acid from market instead of producing the same from Ethanol or Acetaldehyde.
As a result of this, production of Acetaldehyde, which is an intermediate product for Acetic Acid, was low.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Pentokey Organy (India) Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Pentokey Organy (India) Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 39,829 Cr while Market cap of Pentokey Organy (India) Ltd is 29 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Pentokey Organy (India) Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Pentokey Organy (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Pentokey Organy (India) Ltd?

As of May 5, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2351.1. On the other hand, Pentokey Organy (India) Ltd stock price is INR ₹46.53.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Pentokey Organy (India) Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Pentokey Organy (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.